Fremanezumab
- Generic Name
- Fremanezumab
- Brand Names
- Ajovy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1655501-53-3
- Unique Ingredient Identifier
- PF8K38CG54
- Background
Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. Along with other recently approved anti-CGRP therapies such as galcanezumab, erenumab, and the oral CGRP antagonist ubro...
- Indication
Fremanezumab is indicated for the preventative treatment of migraine in adults.
- Associated Conditions
- Migraine
- Associated Therapies
- -
Fremanezumab for the Prevention of Menstrually-related Migraine Attacks
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 120
- Registration Number
- NCT06659120
- Locations
- 🇨ðŸ‡
Department of Neurology, Inselspital, Bern, Switzerland
Migraine Medication Effects on Urinary Symptoms
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 200
- Registration Number
- NCT06212661
- Locations
- 🇺🇸
Cleveland Clinic, Main Campus, Cleveland, Ohio, United States
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
- Conditions
- Interventions
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT06173661
- Locations
- 🇺🇸
Brigham and Women's Health Care Center, Chestnut Hill, Massachusetts, United States
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT05458011
- Locations
- 🇨🇳
Teva Investigational Site 88022, Changsha Shi, China
🇨🇳Teva Investigational Site 88015, Suzhou Shi, China
🇨🇳Teva Investigational Site 88023, Tianjin Shi, China
Real World Effectiveness of Eptinezumab in Participants With Migraine
- Conditions
- Interventions
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 32
- Registration Number
- NCT05284019
- Locations
- 🇺🇸
Gilbert Neurology Partners/ CCT Research, Gilbert, Arizona, United States
🇺🇸Ki Clinical Research LLC, dba New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸Innovation Medical Group, Palmetto Bay, Florida, United States
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
- Conditions
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Austrian Migraine Registry Collaboration
- Target Recruit Count
- 1500
- Registration Number
- NCT05281770
- Locations
- 🇦🇹
Medical University Innsbruck, Innsbruck, Tirol, Austria
🇦🇹Clinic Hietzing, Vienna, Austria
🇦🇹Medizinische Universität Wien, Wien, Vienna, Austria
CGRP Inhibition, Autonomic Function, and Migraine
- Conditions
- Interventions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 120
- Registration Number
- NCT04628429
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 476
- Registration Number
- NCT04530110
- Locations
- 🇮🇹
Teva Investigational Site 30230, Firenze, Italy
🇮🇹Teva Investigational Site 30239, Milano, Italy
🇮🇹Teva Investigational Site 30228, Milano, Italy
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years of Age
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 278
- Registration Number
- NCT04464707
- Locations
- 🇺🇸
Teva Investigational Site 14322, Los Angeles, California, United States
🇺🇸Teva Investigational Site 14361, Sacramento, California, United States
🇺🇸Teva Investigational Site 14319, Aurora, Colorado, United States
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 235
- Registration Number
- NCT04458857
- Locations
- 🇺🇸
Teva Investigational Site 14281, Little Rock, Arkansas, United States
🇺🇸Teva Investigational Site 14253, Banning, California, United States
🇺🇸Teva Investigational Site 14370, Loma Linda, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.